Challenge

A prominent global biopharmaceutical leader, ranked among the top 5, encountered generic competition for its leading cardiovascular drug. This challenge was coupled with various countries implementing contracting and access limitations. In response, they engaged DKI Health to comprehensively understand:

• Cost containment measures, prevailing trends, and the resulting effects on patient treatment.

• Key Opinion Leaders (KOLs), Subject Matter Experts (SMEs), patient advocacy and policy groups, and organizations actively engaged in matters related to both cost containment and patient care.

• Messaging relevant to stakeholders in these areas.

Our Solution

• Assessed over 200 sources, encompassing a diverse array, ranging from government regulations, Health Technology Assessment (HTA) reports, payer policies, peer-reviewed and pharmaceutical media articles to expert and patient advocate commentary, industry publications, and whitepapers.

• Surveyed and met with country teams to understand their needs and challenges in engaging with decision makers; views of stakeholders, including patients and advocates, and their impacts on access decisions.

• Developed a comprehensive report with recommendations detailing:

  • country cost containment measure use (both individually and through comparison);

  • measures most likely to impact client drug/contracting near-term, and options to address them;

  • planned and likely changes to measure design and use;

  • influencers and experts, prioritized based on their geographic location and their expertise and messaging.

Benefit to Client

• Identification of Key Measures: Ability to identify pivotal measures likely to (negatively) impact their drug and how to address them.

• Country-Specific Challenges and Contracting Implications: Discern distinct challenges in each country and implications for contracting.

• Influencer Identification and Collaboration Prospects: Identify influential figures responsible for managing cost-containment measures while highlighting opportunities for valuable collaborations and partnerships.